Located in Sunnyvale, California and Plymouth, Minnesota, Silk Road Medical is focused on reducing stroke risk through a carotid artery disease treatment called TransCarotid Artery Revascularization (TCAR). The company announced last month that CEO Erica Rogers intended to retire. She will continue serving as an advisor to the board.
The company’s plan included Rogers formally retiring once Silk Road completed the succession process. The company enlisted executive search firm Spencer Stuart to help find a replacement CEO. It now has a successor to the CEO who held the corner office for 11 years: Chas McKhann.
“Chas is a skilled and experienced leader with a track record of effectively building and scaling medical device businesses into underpenetrated markets. We are excited to welcome him to Silk Road,” said Jack Lasersohn, chair of the company’s board. “We thank Erica Rogers for her leadership and contributions to Silk Road over the last 11 years, and we look forward to our next phase of growth as we continue expanding the use of transcarotid artery revascularization (TCAR).”
McKhann brings more than 25 years of experience in the medical device industry, including a number of C-suite positions. Most recently, he served as president and CEO at Apollo Endosurgery before Boston Scientific acquired it for $615 million in April.
Before Apollo Endosurgery, McKhann held leadership positions at companies including Torax Medical and Intersect ENT, among others.
“I am thrilled to join Silk Road Medical as the company’s CEO,” said McKhann. “I look forward to working closely with the leadership team and Board of Directors to build upon Silk Road’s track record of growth, advance the company’s progress toward establishing TCAR as the minimally invasive standard of care in carotid artery disease, and continue delivering on the company’s mission to reduce the risk of stroke and its devastating impact for patients.”
